非酒精性脂肪性肝病合并2型糖尿病患者肝组织病理学变化研究

doi:10.3969/j.issn.1672-5069.2017.04.010

摘要/Abstract

摘要： 目的研究非酒精性脂肪性肝病（NAFLD）合并2型糖尿病（T2DM）患者肝脏组织病理学变化。方法分析240例行肝活检术的NAFLD患者临床资料,比较NAFLD合并T2DM与未合并T2DM患者肝组织病理学表现和评分的差异。结果在240例NAFLD患者中,合并2型糖尿病者80例（33.3%）,未合并T2DM 者160例（66.7%）;在NAFLD合并T2DM患者中非酒精性脂肪性肝炎（NASH）60例、肝纤维化20例,未合并T2DM患者中分别为68例和92例;在NAFLD合并T2DM患者中检出肝纤维化评分≥2者30例（37.5%）、肝细胞气球样变评分≥2者23例（28.8%）和马洛里小体22例（27.5%）,均显著高于未合并T2DM患者的【20例（12.5%）、22例（13.8%）和30例（18.8%）,P<0.05】;T2DM为发生NASH（OR=3.27,95%CI：1.42~7.55）和肝纤维化（OR=3.35,95%CI：1.55~7.63）的独立危险因素。结论合并T2DM的NAFLD患者肝组织病理学损伤更趋严重,应注意防治。

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 非酒精性脂肪性肝炎, 肝纤维化, 病理学

Abstract: Objective To investigate the pathological changes of liver tissues in patients with nonalcoholic fatty liver disease（NAFLD） and type 2 diabetes mellitus （T2DM）. Methods The clinical data of 240 patients with biopsy proven NAFLD were analyzed. Histopathology findings of livers were compared between patients with and without T2DM. Results Out of the 240 patients,there were 80（33.3%） patients with NAFLD and T2DM,and 160 （66.7%） patients with NAFLD without T2DM;Nonalcoholic steatohepatitis （NASH） and liver fibrosis were found in 60 and 20 patients with NAFLD and T2DM,while they were in 68 and 98 patients with NAFLD without T2DM;Patients with NAFLD and T2DM had higher rates of liver fibrosis score≥2（37.5%,n=30）,ballooning score≥2（28.8%,n=23） and Mallory body（27.5%,n=22） compared to patients with NAFLD without T2DM （12.5%,n=20;13.8%,n=22 and 18.8%,n=30,P<0.05）;T2DM was independently associated with NASH （OR = 3.27,95%CI:1.42-7.55） and advanced fibrosis（OR=3.35,95%CI:1.55-7.63） in all patients with NAFLD. Conclusion The liver pathological changes in patients with NAFLD and T2DM might be severe,which warrants more attention.

Key words: Nonalcoholic fatty liver disease, Type 2 diabetes mellitus, Nonalcoholic steatohepatitis, Liver fibrosis, Pathology

刘晓妮, 王颖, 李桃桃, 马小敏. 非酒精性脂肪性肝病合并2型糖尿病患者肝组织病理学变化研究[J]. 实用肝脏病杂志, 2017, 20(4): 420-423.

Liu Xiaoni, Wang Ying, Li Taotao, et al.. Pathological changes of liver tissues in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 420-423.

参考文献

[1] 梁乾飞,赵彩彦. 非酒精性脂肪性肝病与肝细胞癌发生. 实用肝脏病杂志,2016,19（1）:113-116.
[2] 舒泳翔,吴鹏波,郭芳,等. 非酒精性脂肪性肝病发病机制的研究进展. 胃肠病学和肝病学杂志,2015,24（8）:901-903.
[3] Lonardo A,Ballestri S,Targher G,et al. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Diabetologia,2016,9（6）:1-22.
[4] Jandorf S,Siersma V,K sterrasmussen R,et al. The impact of patients' involvement in cooking on their mortality and morbidity:A 19-year follow-up of patients diagnosed with type 2 diabetes mellitus. Scan J Prim Health Care,2015,33（1）:33-39.
[5] 王慧慧,闫晓光,马佳妮,等. 新诊断2型糖尿病合并非酒精性脂肪性肝病患者血浆内脂素及视黄醇结合蛋白4的表达水及其与胰岛素抵抗的关系. 中国医药导报,2015,12（33）:98-101.
[6] Takahashi Y,Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Metab Clin Experiment,2015,191（2）:235-240.
[7] Polyzos SA,Goulis DG,Kountouras J,et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones,2014,13（4）:1226-1233.
[8] 陈燕铭. 糖尿病的最新诊断标准. 国际医药卫生导报,1999,1（5）:1-10.
[9] 李瑜元. 非酒精性脂肪性肝病诊疗指南（2006年2月修订）. 现代消化及介入诊疗,2007,12（4）:266-268.
[10] 刘斌. 非酒精性脂肪性肝病中医证型与血生化多指标的差异性研究. 上海中医药大学,2015.
[11] 徐利君,陈赛贞,徐红燕,等. 银杏叶片对土三七诱导大鼠肝小静脉闭塞病的干预作用. 浙江中西医结合杂志,2016,26（6）:525-528.
[12] Puchakayala BK,Verma S,Kanwar P,et al. Histopathological differences utilizing the nonalcoholicfatty liver disease activity score criteria in diabetic（type2 diabetes mellitus） and non-diabetic patients withnonalcoholic fatty liver disease. World J Hepatol,2015,7（25）:2610-2618.
[13] Xu MY,Jia XF,Qu Y,et al. Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B. J Translat Med,2013,11（1）:3955-3957.
[14] 宗蕾,陆伦根. 抗氧化剂治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎的循证医学证据. 肝脏,2009,14（4）:334-337.
[15] Mhetre BJ,Honnutagi RM,Biradar MS,et al. Prevalence of non-alcoholic fatty liver disease（NAFLD） in Hispanics with diabetes mellitus type 2（T2DM） and role of treatment. Int J Biomed Adv Res,2016,7（2）:97-101.
[16] 张秀梅,胡长军,崔兆辉,等. 2型糖尿病并发非酒精性脂肪性肝病发病机制的研究进展.现代生物医学进展,2013,13（7）:1389-1391.
[17] Angulo P,Keach JC,Batts KP,et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology,1999,30（6）:1356-1362.
[18] 陆伦根. 肝纤维化非创伤性诊断临床研究进展.中华医学会第11次全国消化系疾病学术会议,2011.
[19] 丰锦春,李军,徐丽红,等. 实时组织弹性成像及血清学指标评估乙型肝炎患者肝纤维化程度及门静脉压力研究.中国全科医学,2015,1（30）:3753-3758.
[20] 张大鹍,陈敏,刘阳,等. ARFI与APRI指数对非酒精性脂肪性肝病肝纤维化的诊断价值.中国临床医学影像杂志,2013,24（3）:178-181.